Overview

Gender

male

Over his career, David has worked on multiple immuno-oncology programs at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca Immuno-oncology Franchise, responsible for the strategy and execution of the Company’s late stage IO programme. Prior to that, he was Head of the early stage oncology programme at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action and predict benefit from IO therapies.

David received a bachelors of science from the Massachusetts Institute of Technology and MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins Hospital.